Palbociclib plus endocrine therapy significantly enhances overall survival of HR +/ HER2 ‐ metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting‐a large institutional study

Title
Palbociclib plus endocrine therapy significantly enhances overall survival of HR +/ HER2 ‐ metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting‐a large institutional study
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-02-08
DOI
10.1002/ijc.33959

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started